View Older Stories View More Recent Stories
-
Notable 52-Week Highs and Lows 4/8: (ADXS) (LULU) (DG) High; (SPPI) (CEQP) Low
-
Door Now Open for Sandoz's Generic Version of Spectrum Pharma's (SPPI) Fusilev; Roth Affirms at 'Neutral'
-
Notable Analyst Rating Changes 4/8: (XRX) (LULU) (HOLI) Upgraded; (WBMD) (AAPL) (NLY) Downgraded
-
Roth Capital Starts Energous Corp (WATT) at Buy
-
Streetinsider.com's Hot Lunchtime Reads 4/6: (RAD) (ALTR) (EMN) (NOW) (CYTX)
-
Synta Pharmaceuticals Closes Public Offering of Common Stock
-
Celution System Clearance in China is 'Major Win' for Cytori (CYTX) - Roth Capital
-
Conatus Pharmaceuticals (CNAT) Prices 3.5M Common Offering at $5.75/Share
-
Conatus Announces Pricing of Public Offering of Common Stock
-
Conatus Announces Pricing of Public Offering of Common Stock
-
Conatus Pharmaceuticals (CNAT) Falls on Plans to Offer Common Stock
-
Conatus Announces Proposed Public Offering of Common Stock
-
Conatus Announces Proposed Public Offering of Common Stock
-
Multiple Positives Appear from Latest Publication of Lion Biotech's (LBIO) TIL Data - Roth
-
Roth Remains Positive on Concert Pharma (CNCE) Following Equity Offering; Affirms 'Buy' Rating
-
Roth Places RGS Energy (RGSE) 'Under Review' Ahead of Q4, FY14 Report
-
Synta Pharma (SNTA) Prices 22M Common Offering at $1.75/Share
-
RMG Networks Reports Fourth Quarter and Year End 2014 Results
-
Roth Capital Downgrades Hyperion Therapeutics (HPTX) to Neutral
-
UPDATE: Can-Fite BioPharma's (CANF) CF101 Phase 2/3 Missed Primary Endpoint; Roth Downgrades to Neutral
-
Streetinsider.com's Hot Lunchtime Reads 3/30: (MGA) (YELP) (AAPL) (BBRY)
-
Lion Biotechnologies (LBIO) Receives First External Validation of Phase I TIL/Yervoy in Metastatic Melanoma; Roth Capital Affirms at 'Buy'
-
Roth Affirms Ligand (LGND) at 'Buy' Following Amgen (AMGN), Spectrum (SPPI) Updates
-
Roth Capital Downgrades Superior Drilling Products (SDPI) to Neutral
-
Roth Capital Downgrades FutureFuel Corp. (FF) to Neutral
-
SolarEdge Technologies (SEDG) IPO Opens Up 11%
-
ROTH Capital Partners Expands Banking Practice with the Addition of David T. Farina, CFA as a Managing Director, Investment Banking
-
Roth Comments on Galena's (GALE) Expanded NeuVax, Trastuzumab Enrollments; Affirms 'Buy' Rating
-
SolarEdge Technologies, Inc. Announces Pricing of Its Initial Public Offering
-
Low ASPs, Higher Operating Expenses Push Yingli Green Energy (YGE) to Wider-than-Expected Q4 Loss - Roth
-
Roth Capital Starts Argos Therapeutics (ARGS) at Buy
-
BioLineRx's (BLRX) BL-8040 Better Positioned as SOC Alternate in SC Mobilization - Roth Capital
-
RMG Networks (RMGN) Announces $25M Conv. Preferred Offering
-
RMG Networks Raises $25 Million in Private Placement of Convertible Preferred Stock
-
Mad Catz (MCZ) Enters 8.98M Common, 4.49M Warrants Direct Offering
-
Mad CatzĀ® Announces $3.7 Million Registered Direct Offering
-
Concert Pharmaceuticals Announces Completion of Public Offering
-
GenVec (GNVC) FY14 Results Flat with Views; Hearing Loss Phase I Update Encouraging - Roth Capital
-
PRESERVATION I Study is Key Upcoming Milestone for BioLineRx (BLRX); Roth Affirms at 'Buy'
-
Can-Fite Bio Pharma's (CANF) CF101 Receives Additional Validation with Latest Agreement - Roth
-
Notable Analyst Rating Changes 3/23: (SPLS) (ELY) (NMM) Upgraded; (NVDA) (CCL) (SHW) Downgraded
-
UPDATE: Roth Capital Downgrades MEI Pharma (MEIP) to Neutral; Future of Pracinostat Now in Question
-
Bluebird Bio (BLUE) PT Raised to $145 at Roth Capital
-
Concert Pharma (CNCE) Prices 3.3M Common Stock Offering at $15.15/Share
-
Concert Pharmaceuticals Announces Pricing of Public Offering
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
MLP Benefit Likely $3 to $6/Share for Green Plains (GPRE); Roth Affirms at 'Buy'
-
Can-Fite BioPharma (CANF) Reaches Important Milestone; Psoriasis Data Expected Soon - Roth
-
Roth Capital Downgrades RSP Permian, Inc. (RSPP) to Neutral

